Overview of Covid-19 Regarding the Cardiovascular Situation in the Light of Current Reports.

Q2 Medicine Cardiovascular and Hematological Disorders - Drug Targets Pub Date : 2020-01-01 DOI:10.2174/1871529X20666200701110045

Suna Aydin, Ramazan Fazil Akkoc, Suleyman Aydin

{"title":"Overview of Covid-19 Regarding the Cardiovascular Situation in the Light of Current Reports.","authors":"Suna Aydin, Ramazan Fazil Akkoc, Suleyman Aydin","doi":"10.2174/1871529X20666200701110045","DOIUrl":null,"url":null,"abstract":"<p><p>Nowadays Coronavirus Disease 2019 (Covid-19) is increasing mortality all over the world mercilessly. We are learning almost every day about its new symptoms and that it mutates quickly. This disease has tied us up and made us desperate. The death rate from this disease has increased in patients who had pre-existing medical conditions, especially cardiovascular ones, by eliminating the angiotensin-converting enzyme (ACE)-2 receptor in the lungs. Also, ACE1 and angiotensin receptor blockers (ARB) may stimulate ACE2 expression and worse the prognosis. Intravenous infusions of ACEIs and ARBs in experimental animals increase the number of ACE2 receptors. Therefore, it may be one of the reasons that COVID-19 infects the cells of patients treating hypertension. However, most of the congress of cardiology do not recommend to discontinue these anti-hypertensive drugs. Therefore, this brief report evaluates Covid-19 in the view of cardiovascular diseases taking into account current reports and suggests some possible solutions to keep the virus under control.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 3","pages":"181-184"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Disorders - Drug Targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X20666200701110045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Nowadays Coronavirus Disease 2019 (Covid-19) is increasing mortality all over the world mercilessly. We are learning almost every day about its new symptoms and that it mutates quickly. This disease has tied us up and made us desperate. The death rate from this disease has increased in patients who had pre-existing medical conditions, especially cardiovascular ones, by eliminating the angiotensin-converting enzyme (ACE)-2 receptor in the lungs. Also, ACE1 and angiotensin receptor blockers (ARB) may stimulate ACE2 expression and worse the prognosis. Intravenous infusions of ACEIs and ARBs in experimental animals increase the number of ACE2 receptors. Therefore, it may be one of the reasons that COVID-19 infects the cells of patients treating hypertension. However, most of the congress of cardiology do not recommend to discontinue these anti-hypertensive drugs. Therefore, this brief report evaluates Covid-19 in the view of cardiovascular diseases taking into account current reports and suggests some possible solutions to keep the virus under control.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

从当前报告看2019冠状病毒病心血管疫情概况

如今，2019冠状病毒病(Covid-19)正在无情地增加世界各地的死亡率。我们几乎每天都在了解它的新症状，而且它变异得很快。这种疾病把我们束缚住了，使我们绝望。由于肺部血管紧张素转换酶(ACE)-2受体的消失，这种疾病的死亡率在已有疾病，特别是心血管疾病的患者中有所增加。此外，ACE1和血管紧张素受体阻滞剂(ARB)可能刺激ACE2表达，使预后恶化。实验动物静脉输注acei和arb可增加ACE2受体的数量。因此，这可能是COVID-19感染高血压患者细胞的原因之一。然而，大多数心脏病学大会不建议停用这些抗高血压药物。因此，本简短报告结合现有报告，从心血管疾病的角度对Covid-19进行评估，并提出一些可能的解决方案，以控制病毒。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cardiovascular and Hematological Disorders - Drug Targets Medicine-Cardiology and Cardiovascular Medicine

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.